Terms: = Head and neck cancer AND MYH9, P35579, 4627, ENSG00000100345, DFNA17
30 results:
1. Genetic predisposition to differentiated thyroid cancer in the Polish population.
Borowczyk M; Sypniewski M; Szyda J; Braszka M; Ziemnicka K; Ruchała M; Oszywa M; Król ZJ; Dobosz P
Pol Arch Intern Med; 2024 Mar; 134(3):. PubMed ID: 38165228
[TBL] [Abstract] [Full Text] [Related]
2. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing myh9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.
Cui L; Lu Y; Zheng J; Guo B; Zhao X
J Exp Clin Cancer Res; 2023 Dec; 42(1):335. PubMed ID: 38057867
[TBL] [Abstract] [Full Text] [Related]
3. DNAJA4 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma via PSMD2-mediated myh9 degradation.
Zhang Q; Feng P; Zhu XH; Zhou SQ; Ye ML; Yang XJ; Gong S; Huang SY; Tan XR; He SW; Li YQ
Cell Death Dis; 2023 Oct; 14(10):697. PubMed ID: 37875476
[TBL] [Abstract] [Full Text] [Related]
4. SAMD9 Promotes Postoperative Recurrence of Esophageal Squamous Cell Carcinoma by Stimulating myh9-Mediated GSK3β/β-Catenin Signaling.
Li Q; Luo H; Dai FQ; Wang RT; Fan XQ; Luo YY; Deng MS; Wang Y; Long T; Guo W; Xu B; Xu CX; Jin H
Adv Sci (Weinh); 2023 Apr; 10(11):e2203573. PubMed ID: 36757050
[TBL] [Abstract] [Full Text] [Related]
5. Identification of TLN1 as a prognostic biomarker to effect cell proliferation and differentiation in acute myeloid leukemia.
Cui D; Cui X; Xu X; Zhang W; Yu Y; Gao Y; Mei C; Zheng W
BMC Cancer; 2022 Sep; 22(1):1027. PubMed ID: 36175877
[TBL] [Abstract] [Full Text] [Related]
6. myh9 Facilitates Cell Invasion and Radioresistance in head and neck cancer via Modulation of Cellular ROS Levels by Activating the MAPK-Nrf2-GCLC Pathway.
You GR; Chang JT; Li YL; Huang CW; Tsai YL; Fan KH; Kang CJ; Huang SF; Chang PH; Cheng AJ
Cells; 2022 Sep; 11(18):. PubMed ID: 36139430
[TBL] [Abstract] [Full Text] [Related]
7. myh9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis.
Kai JD; Cheng LH; Li BF; Kang K; Xiong F; Fu JC; Wang S
Cell Biol Int; 2022 Dec; 46(12):2085-2094. PubMed ID: 36030536
[TBL] [Abstract] [Full Text] [Related]
8. The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress myh9-mediated c-Myc deubiquitination in lung adenocarcinoma.
Liu JH; Yang HL; Deng ST; Hu Z; Chen WF; Yan WW; Hou RT; Li YH; Xian RT; Xie YY; Su Y; Wu LY; Xu P; Zhu ZB; Liu X; Deng YL; Wang YB; Liu Z; Fang WY
Acta Pharmacol Sin; 2022 Oct; 43(10):2687-2695. PubMed ID: 35296779
[TBL] [Abstract] [Full Text] [Related]
9. "myh9 mutation and squamous cell cancer of the tongue in a young adult: a novel case report".
Yabe TE; King K; Russell S; Satgunaseelan L; Gupta R; Chen J; Ashford B
Diagn Pathol; 2022 Feb; 17(1):23. PubMed ID: 35125114
[TBL] [Abstract] [Full Text] [Related]
10. Chemically synthesized cinobufagin suppresses nasopharyngeal carcinoma metastasis by inducing ENKUR to stabilize p53 expression.
Hou R; Liu X; Yang H; Deng S; Cheng C; Liu J; Li Y; Zhang Y; Jiang J; Zhu Z; Su Y; Wu L; Xie Y; Li X; Li W; Liu Z; Fang W
Cancer Lett; 2022 Apr; 531():57-70. PubMed ID: 35114328
[TBL] [Abstract] [Full Text] [Related]
11. Knockdown of circ_NEK6 Decreased
Chen F; Yin S; Feng Z; Liu C; Lv J; Chen Y; Shen R; Wang J; Deng Z
Technol Cancer Res Treat; 2021; 20():15330338211004950. PubMed ID: 33759638
[TBL] [Abstract] [Full Text] [Related]
12. Genomic Sequencing of cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma.
Uchi R; Jiromaru R; Yasumatsu R; Yamamoto H; Hongo T; Manako T; Sato K; Hashimoto K; Wakasaki T; Matsuo M; Nakagawa T
Anticancer Res; 2021 Jan; 41(1):71-79. PubMed ID: 33419800
[TBL] [Abstract] [Full Text] [Related]
13. Association of Human Papillomavirus With Oral Lichen Planus and Oral Leukoplakia: A Meta-analysis.
Shang Q; Peng J; Zhou Y; Chen Q; Xu H
J Evid Based Dent Pract; 2020 Dec; 20(4):101485. PubMed ID: 33303094
[TBL] [Abstract] [Full Text] [Related]
14. Cisplatin-Mediated Upregulation of APE2 Binding to myh9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury.
Hu Y; Yang C; Amorim T; Maqbool M; Lin J; Li C; Fang C; Xue L; Kwart A; Fang H; Yin M; Janocha AJ; Tsuchimoto D; Nakabeppu Y; Jiang X; Mejia-Garcia A; Anwer F; Khouri J; Qi X; Zheng QY; Yu JS; Yan S; LaFramboise T; Anderson KC; Herlitz LC; Munshi NC; Lin J; Zhao J
Cancer Res; 2021 Feb; 81(3):713-723. PubMed ID: 33288657
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological and molecular characterisation of USP6-rearranged soft tissue neoplasms: the evidence of genetic relatedness indicates an expanding family with variable bone-forming capacity.
Wang JC; Li WS; Kao YC; Lee JC; Lee PH; Huang SC; Tsai JW; Chen CC; Chang CD; Yu SC; Huang HY
Histopathology; 2021 Apr; 78(5):676-689. PubMed ID: 33000481
[TBL] [Abstract] [Full Text] [Related]
16. CRLF1-myh9 Interaction Regulates Proliferation and Metastasis of Papillary Thyroid Carcinoma Through the ERK/ETV4 Axis.
Yu ST; Sun BH; Ge JN; Shi JL; Zhu MS; Wei ZG; Li TT; Zhang ZC; Chen WS; Lei ST
Front Endocrinol (Lausanne); 2020; 11():535. PubMed ID: 32982961
[TBL] [Abstract] [Full Text] [Related]
17. myh9 promotes cell metastasis
Yang B; Liu H; Bi Y; Cheng C; Li G; Kong P; Zhang L; Shi R; Zhang Y; Zhang R; Cheng X
Int J Med Sci; 2020; 17(13):2013-2023. PubMed ID: 32788880
[TBL] [Abstract] [Full Text] [Related]
18. FNDC3B 3'-UTR shortening escapes from microRNA-mediated gene repression and promotes nasopharyngeal carcinoma progression.
Li YQ; Chen Y; Xu YF; He QM; Yang XJ; Li YQ; Hong XH; Huang SY; Tang LL; Liu N
Cancer Sci; 2020 Jun; 111(6):1991-2003. PubMed ID: 32232887
[TBL] [Abstract] [Full Text] [Related]
19. PTP1B up-regulates EGFR expression by dephosphorylating myh9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
Pan BQ; Xie ZH; Hao JJ; Zhang Y; Xu X; Cai Y; Wang MR
Biochem Biophys Res Commun; 2020 Jan; 522(1):53-60. PubMed ID: 31735331
[TBL] [Abstract] [Full Text] [Related]
20. Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Liu Y; Jiang Q; Liu X; Lin X; Tang Z; Liu C; Zhou J; Zhao M; Li X; Cheng Z; Li L; Xie Y; Liu Z; Fang W
EBioMedicine; 2019 Oct; 48():386-404. PubMed ID: 31594754
[TBL] [Abstract] [Full Text] [Related]
[Next]
